Replies to post #9107 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

Will TEVA be able to extend the patent protection for Copaxone with this newer formulation?

Teva should be able to get patent protection for the new thrice-weekly 40mg formulation, but this has no effect on the Copaxone patents being litigated between Teva, NVS/MNTA, and MYL, all of which pertain to regular Copaxone (which is dosed 20mg daily).

As noted in #msg-72989576, the thrice-weekly 40mg formulation of Copaxone will be a distinct branded drug and will not be substitutable for a prescription written for regular Copaxone.